BGIM
ABBV icon

Boussard & Gavaudan Investment Management’s AbbVie ABBV Stock Holding History

Boussard & Gavaudan Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-120,000
Closed -$21.1M – 60
2024
Q4 		$21.1M Buy
+120,000
New +$22.1M 1.76% 17

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Boussard & Gavaudan Investment Management's ABBV Position: Q1 2025 in Review

Boussard & Gavaudan Investment Management sold out of AbbVie (ABBV) in Q1 2025, closing a stake of 120,000 shares — an estimated $21.1M sold.

Boussard & Gavaudan Investment Management first reported a position in ABBV in Q4 2024 and held it in 1 quarter. The position peaked at $21.1M in Q4 2024. 3,822 funds tracked by Wall St. Rank hold ABBV as of Q1 2025.

  • Boussard & Gavaudan Investment Management reported no remaining AbbVie position as of Q1 2025 after selling out during the quarter.
  • Boussard & Gavaudan Investment Management sold 120,000 AbbVie shares in Q1 2025, an estimated $21.1M.
  • Boussard & Gavaudan Investment Management first reported a position in AbbVie in Q4 2024 and held it in 1 quarter.
  • Boussard & Gavaudan Investment Management's AbbVie position peaked at $21.1M in Q4 2024.
  • 3,822 funds tracked by Wall St. Rank held AbbVie as of Q1 2025.

Based on Boussard & Gavaudan Investment Management's 13F filing for Q1 2025, filed 15 May 2025.